Keith Williams

Husband, Father, & guy who uses terrible jokes on the wait staff…PAH representative for Merck.

[Merck @Merck]

Today, the FDA approved an updated label for a treatment option for adults living with pulmonary arterial hypertension (#PAH).

Read more: https://t.co/nSK6VD0gmo

[Victor M. Moles @victor_moles]

Just a few weeks left until PH Update 2026 in Ann Arbor! ⏳🫁

If you treat or manage pulmonary hypertension, this full-day symposium brings together leading clinical experts to discuss the latest management strategies, emerging therapies, and clinical trials.

🗓️ Friday, Oct 2

📍 Ann Arbor, MI

🎓 Up to 7.0 CME/CNE/CPE credits

Spaces are filling up—reserve your seat today:

https://t.co/by8QWdikfU

@anjalivaidyaMD @heresi_gustavo @umichCVC @umichmedicine @ValMcLaughlinMD @SandeepSahayMD @jeanlucvachiery @OSitbon @CHESTPulmCardio @AlbertaPHdoc @atscommunity @PulmonaryNews @PHAssociation @yreddyhf

[Victor M. Moles @victor_moles]

Ready to elevate your practice in Pulmonary Hypertension care? 🫁

Don't miss PH Update 2026 in Ann Arbor on Oct 2nd! Join top experts for cutting-edge insights & earn up to 7.0 CME/CNE/CPE credits.

Secure your spot now! 👇 https://t.co/by8QWdikfU

A message from @ValMcLaughlinMD:
https://t.co/spSKMPgkfg

@jeanlucvachiery @SandeepSahayMD @robertbadaglia1 @heresi_gustavo @anjalivaidyaMD @AlbertaPHdoc @OSitbon @yreddyhf @AssociationWsph @atscommunity @CHESTPulmCardio @PulmonaryNews @umichCVC @umichmedicine

[Merck @Merck]

Today, we’re proud to announce the U.S. FDA approved the first oral PCSK9 inhibitor, providing a new treatment option as an adjunct to diet and exercise for adults living with #hypercholesterolemia, or high LDL cholesterol (LDL-C). Learn more about our approval here: https://t.co/ZCZLLZyK65

[Victor M. Moles @victor_moles]

Headline: Don't miss out on the PH Update 2026! 🗓️
Join us in Ann Arbor on Friday, October 2nd, for a comprehensive, full-day symposium serving as your official Gateway to the 8th World Symposium on Pulmonary Hypertension.
Whether you are a physician, nurse, or pharmacist, this is your opportunity to elevate your practice with the latest insights in PH management while earning valuable continuing education credits.
🔍 Event Highlights:
📍 Location: Sheraton Ann Arbor Hotel (Ann Arbor, MI)
🧠 Credits: Earn up to 7.0 CME / CNE / CPE credits
🎙️ Featuring: Global experts and cutting-edge clinical updates
Secure your spot today and stay ahead of the curve in pulmonary hypertension care.
👉 Register here: https://t.co/by8QWdikfU
#PHUpdate #WSPH @umichCVC @ValMcLaughlinMD @jeanlucvachiery @robertbadaglia1 @sonjabart @rchannick @heresi_gustavo @VIRkhaja @SteveMathaiMD @SandeepSahayMD @anjalivaidyaMD @AlbertaPHdoc @OSitbon @yreddyhf

[Keith Williams @thewizzams]

OVERVIEW - PH Update 2026: Gateway to the 8th World Symposium https://t.co/oJqmhka3AW

[Merck @Merck]

We’re sharing data for our Phase 2 study in an uncommon type of pulmonary hypertension at #ACC26. Read more: https://t.co/Axx0LsHH4h

[Keith Williams @thewizzams]

@thepointsguy Booked a flight involving two connections

[Merck @Merck]

We’re pleased to announce topline results from our Phase 2 study in a type of pulmonary hypertension (#PH). Learn more here: https://t.co/9UkwB6yjFL

[Merck @Merck]

We’re proud to announce the #FDA approval of a label update for a treatment option for patients with pulmonary arterial hypertension (#PAH). Learn more here: https://t.co/AaBFVP4oik

[NEJM @NEJM]

Presented at #ERSCongress:

Among adults with pulmonary arterial hypertension who had received the diagnosis less than 1 year earlier, the addition of sotatercept to background therapy resulted in a lower risk of clinical worsening than placebo. Full HYPERION phase 3 trial results: https://t.co/dfkgglg0hd

@EuroRespSoc

[U-M Health Frankel CVC @umichCVC]

Prescribing sotatercept alongside standard treatment for pulmonary arterial hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a new study in @NEJM led by @ValMcLaughlinMD: https://t.co/GdbahP0Y2u

[Keith Williams @thewizzams]

@reflog18 Facts.

[Merck @Merck]

We’re pleased to announce the #FDA has granted priority review to our application related to pulmonary arterial hypertension (#PAH). Learn more here: https://t.co/4qsH9Z1qaW

[Merck @Merck]

Today, we announced new data from our Phase 3 trial in pulmonary arterial hypertension (#PAH) at #ACC25. Learn more about our latest cardiovascular update: https://t.co/E0tF64NGK9

[Victor M. Moles @victor_moles]

Wow! Great news for the #PAH community! The #ZENITH clinical trial meets primary endpoint at interim analysis and adds data supporting the use of #sotatercept. An immense honor to be part of this team. @ValMcLaughlinMD @umichCVC @umichmedicine

[American College of Cardiology @ACCinTouch]

ZENITH: Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or 🏥 for worsening #cvPAH compared to placebo in high-risk adults with PAH.

Learn more: https://t.co/3mCcWwK4pg #ACC25

[Frederik Meijer Heart & Vascular Institute @FM_HVI]

Congrats to Dr. @RedaGirgis on the publication of "Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD)" in the @PulmCirc! 📓https://t.co/1dRWJerlJO

[CHEST @accpchest]

The #CHESTHumanities podcast has officially launched with @RanaAwdish, author of “A Kind of Faith,” as the inaugural guest. This #JournalCHEST series explores the intersection of medicine and the human experience.

Listen to the new episode: https://t.co/67V7DeEoWN
#MedHumChat

[Keith Williams @thewizzams]

@_YoungTruth7 …same